EGFR and hepatocellular carcinoma: Collectively, these results indicated that EGFR activation is an important prognostic factor of HCC and relates to acquired Lenvatinib resistance, highlighting that EGFR and its downstream pathway might be a promising therapeutic target of Lenvatinib resistance in this malignancy.